Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm

NSRGY

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Aimmune Therapeutics Inc. (NASDAQ: AIMT) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Sociétés des Produits Nestlé S.A (“SNP”), a wholly owned subsidiary of Nestlé, S.A. (Other OTC: NSRGY).

Click here to learn more and participate in the action.

On August 31, 2020, Aimmune announced that it had signed an agreement to be acquired by SNP for approximately $2.6 billion. Pursuant to the merger agreement, Aimmune stockholders will receive $34.50 in cash for each share of Aimmune common stock owned. The deal is scheduled to close in the fourth quarter of 2020.

Bragar Eagel & Squire is concerned that Aimmune’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Indeed, Aimmune stock has recently traded well above the $34.50 merger consideration. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Aimmune’s stockholders.

If you own shares of Aimmune and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today